
    
      Main inclusion criteria:

        1. AML, any subtype except acute promyelocytic leukemia (APL)

        2. At least one of the following features:

           i. Age 18-75 with adverse risk cytogenetics ii. Age 18-75 with antecedent
           myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD), or therapy-related
           AML iii. Age 60-75, regardless of risk category

        3. No prior therapy for AML other than hydroxyurea

        4. Judged by treating physician to be medically fit for induction chemotherapy

        5. Eastern Cooperative Oncology Group (ECOG) performance status score 0-2

        6. Normal left ventricular ejection fraction

      Subjects will receive induction chemotherapy consisting of idarubicin 12 mg/m2 on Days 1-3
      plus cytarabine 200 mg/m2 (age 18-59) or 100 mg/m2 (age 60-75) as a continuous IV infusion x
      7 days. Volasertib will be administered on day 4 in a dose-escalation schedule, using a
      standard 3+3 dose escalation design, over 3 dose levels. Once the MTD has been determined, an
      additional dose expansion cohort will be accrued.
    
  